Arbutus Biopharma Logo
Arbutus Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 05, 2022 07:30 ET | Arbutus Biopharma Corporation
Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track Well positioned financially with a projected cash runway into the second quarter of 2024 ...
LOGO.png
Draganfly to Complete Listing of its Common Shares on Nasdaq Under the Symbol “DPRO”
July 22, 2021 09:00 ET | Draganfly Inc
Los Angeles, CA, July 22, 2021 (GLOBE NEWSWIRE) -- Draganfly Inc. (OTCQB: DFLYF) (CSE: DFLY) (FSE: 3U8) (“Draganfly”), a drone manufacturer and systems developer, announced today that it expects to...
Arbutus Biopharma Logo
Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent
July 07, 2021 07:00 ET | Arbutus Biopharma Corporation
Phase 2a trial to investigate the safety and anti-viral activity of AB-729 in combination with ongoing nucleos(t)ide analog (NA) therapy and short courses of Peg-IFNα-2a in subjects with chronic...
Arbutus Biopharma Logo
Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection
July 06, 2021 07:00 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa. and OXFORD, United Kingdom, July 06, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) and Vaccitech plc (Nasdaq: VACC) today announced that the companies have...
Arbutus Biopharma Logo
Arbutus Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 05, 2021 07:30 ET | Arbutus Biopharma Corporation
AB-729, Arbutus’ proprietary subcutaneously delivered RNAi agent, continues to demonstrate robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B...
Arbutus Biopharma Logo
Arbutus Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update
March 04, 2021 07:30 ET | Arbutus Biopharma Corporation
AB-729, Arbutus’ proprietary subcutaneously delivered RNAi agent, demonstrates robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV) with...
Arbutus Biopharma Logo
Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus Trial will evaluate Assembly’s core inhibitor candidate, vebicorvir, with Arbutus’ RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy SOUTH SAN FRANCISCO, Calif., and WARMINSTER,...
Arbutus Biopharma Logo
Arbutus Announces 2021 Corporate Objectives and Provides Financial Update
January 25, 2021 07:30 ET | Arbutus Biopharma Corporation
2021 objectives leverage positive momentum in Arbutus’ Hepatitis B research and development programs WARMINSTER, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS),...
Arbutus Biopharma Logo
Arbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B Subjects
December 10, 2020 07:30 ET | Arbutus Biopharma Corporation
Repeat dosing of 60 mg AB-729 every 8 weeks resulted in mean HBsAg declines of –1.37 log10 (N=6) comparable to AB-729 dosed every 4 weeks (–1.44 log10, N=7, p<0.7) AB-729 remains generally safe...
Arbutus Biopharma Logo
Arbutus Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 05, 2020 07:30 ET | Arbutus Biopharma Corporation
Results from an ongoing Phase 1a/1b clinical trial for Arbutus’ AB-729, a subcutaneously delivered RNAi agent, in subjects with chronic hepatitis B virus (HBV) infection, to be presented at the...